Less frequent intake of bisphosphonates promotes compliance;Minder frequent een hoge inname bisfosfonaten bevordert therapietrouw

Pharmaceutisch Weekblad

Volumn 141, Issue 24, 2006, Pages 816-817

  Penning Van Beest, Fernie ^a   Herings, Ron ^a  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP; RISEDRONIC ACID;

ARTICLE; COMPLIANCE (PHYSICAL); DRUG USE; MULTIVARIATE ANALYSIS; UNIVARIATE ANALYSIS;

EID: 33747298567     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Penning-van Beest FJA, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236-42.
2. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother. 2000;1(2):225-38.
3. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-99.
4. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271-87.
5. Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord. 2002;2(1):20-33.
6. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24(11):1871-86.
7. Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48(3):243-51.